

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

5

COMPLETE IF KNOWN

10/706,695

November 12, 2003

Joseph L. Duffy et al.

1

100

21277

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
547		PCT	WO 00/69810		NOVO NORDISK A/S & AGOURON PHARMACEUTICALS, INC.	11/23/2000
	8	PCT	WO 00/39088		NOVO NORDISK A/S & AGOURON PHARMACEUTICALS, INC.	07/06/2000
	9	PCT	WO 99/01423corrected version		NOVO NORDISK A/S & ALANEX CORPORATION	01/14/1999
	10	PCT	WO 99/01423		NOVO NORDISK A/S & ALANEX CORPORATION	01/14/1999
	11	PCT	WO 98/04528 A2		BAYER CORPORATION & BAYER AKTIENGESELLSCHAFT	02/05/1998
	12	PCT	WO 98/04528 A3		BAYER CORPORATION & BAYER AKTIENGESELLSCHAFT	02/05/1998
	13	PCT	WO 99/22108		MERCK & CO., INC.	05/28/1998
	14	PCT	WO 99/22109		MERCK & CO., INC.	05/28/1998
	15	PCT	WO 97/16442		MERCK & CO., INC.	05/09/1997
547	16	PCT	WO 98/21957		MERCK & CO., INC.	05/28/1998

**Examiner
Signature**

S. W. Wang

Date Considered

5-118/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc.

STATEMENT BY APPLICANT

FEB 09 2004

(use as many sheets as necessary)

Sheet

of

5

COMPLETE IF KNOWN

10/706,695

November 12, 2003

Joseph L. Duffy, et al:

1

10

21277

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
5	17	PCT	WO 99/46267		NOVO NORDISK A/S	09/16/1999
	18	PCT	WO 99/32448		AMGEN, INC.	07/01/1999
	19	PCT	WO 99/32448 corrected version		AMGEN, INC.	07/01/1998
	20	PCT	WO 02/18335		YAMANOUCHI PHARMACEUTICAL CO., LTD.	03/07/2002
	21	PCT	WO 01/58890		ASTRAZENECA AB	08/16/2001
	22	PCT	WO 01/46165		NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	06/28/2001
	23	PCT	WO 01/44226		PROTHERICS MOLECULAR DESIGN LIMITED	06/21/2001
	24	PCT	WO 01/40223 A2		NOVARTIS AG	06/07/2001
	25	PCT	WO 01/40223 A3		NOVARTIS AG	06/07/2001
5	26	PCT	WO 01/36415		NOVARTIS AG	05/25/2001

**Examiner
Signature**

G. Wang

Date Considered

518107

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/

STATEMENT BY APPLICANT

FEB 09 2004

(use ~~4~~ as many sheets as necessary)

OIP STATE
 FEB 09 2004
 (use)
 PATENT & TRADEMARK
 Sheet

3

of

5

COMPLETE IF KNOWN

Attorney Docket Number 21277

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
SW	27	PCT	WO 01/32632 A2		ELI LILLY AND COMPANY	05/10/2001
	28	PCT	WO 01/32632 A3		ELI LILLY AND COMPANY	05/10/2001
	29	EP	0 263 071 A1		CIBA-GEIGY AG	04/06/1988
	30	EP	0 263 071 B1		CIBA-GEIGY AG	04/06/1988
	31	EP	0 253 259 A2		BAYER AG	01/20/1988
	32	EP	0 253 259 A3		BAYER AG	01/20/1988
	33	EP	0 193 885 A1		BASF	09/10/1986
	34	EP	0 193 885 B1		BASF	09/10/1986
	35	EP	0 202 538 A1		BAYER AG	11/26/1986
SW	36	EP	0 202 538 B1		BAYER AG	11/26/1986

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

STATEMENT BY APPLICANT

FEB 09 2004

(use as many sheets as necessary)

Sheet

4

of

5

Application Number

10/701.186

Filing Date

November 4, 2003

First Named Inventor

Joseph L. Duffy, et al.

Group Art Unit

Examiner Name

Attorney Docket Number

21167

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
SW	37	EP	0 217 748 A2		CIBA-GEIGY	04/08/1987
	38	EP	0 217 748 B1		CIBA-GEIGY	04/08/1987
	39	FR	2 565 981		ADIR	12/20/1985
	40	FR	2 564 467		ADIR	11/22/1985
	41	DE	35 29 247 A1		BAYER AG	11/20/1986
	42	DE	36 24 304 A1		BAYER AG	01/28/1986
	43	DE	41 19 767 A1		ARZNEIMITTELWERK DRESDEN GmbH	02/15/2002
	44	DE	35 07 421 A1		BASF AG	09/04/1986
SW	45	JP	2002-50169		FUJI PHOTO FILM CO., LTD.	02/15/2002

**Examiner
Signature**

S. Wang


Date Considered

5118107

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	10/706,695
		Filing Date	November 12, 2003
		First Named Inventor	Joseph L. Duffy et al.
		Group Art Unit	
		Examiner Name	
Sheet	5	of	5
		Attorney Docket Number	21277

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
SW	46	Guillon, Jean, et al., "Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non-peptide glucagon receptor antagonist", <i>Eur. J. Med. Chem.</i> , 33, pp. 293-308 (1998)
	47	Petersen, K. F., et al., "Effects of a novel glucagon receptor antagonist (Bay-27-9955) on glucagon-stimulated glucose production in humans", <i>Diabetologia</i> , 44, pp. 2018-2024 (2001)
	48	Ladouceur, Gaetan, H., et al., "Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a New Class of Glucagon Receptor Antagonists", <i>Bioorganic & Medicinal Chemistry Letters</i> , 12, pp. 461-464 (2002)
	49	Cascieri, Margaret, A., "Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor", <i>The Journal of Biological Chemistry</i> , Vol. 274, Issue of March 26, pp. 8694-8697 (1999)
	50	de Laszlo, Stephen, E., "Potent, Orally Absorbed Glucagon Receptor Antagonists", <i>Bioorganic & Medicinal Chemistry Letters</i> , 9, pp. 641-646 (1999)
	51	Madsen, Peter, et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 41, pp. 5150-5157 (1998)
	52	Ling, Anthony, et al., "Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists", <i>J. Med. Chem.</i> , 44, pp. 3141-3149 (2001)
	53	Ling, Anthony, et al., "Human Glucagon Receptor Antagonists Based on Alkylidene Hydrazides", <i>Bioorganic & Medicinal Chemistry Letters</i> , 12, pp. 663-666 (2002)
	54	Collins, Judith, L., "CP-99,711: A Non-Peptide Glucagon Receptor Antagonist", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 2, No. 9, pp. 915-918 (1992)
	55	Parker, Janice, C., "Effects of Skyrin, a Receptor-Selective Glucagon Antagonist, in Rat and human Hepatocytes", <i>Diabetes</i> , Vol. 49, pp. 2079-2086 (December 2000)
	56	Connell, Richard, D., "Glucagon antagonists for the treatment of Type 2 diabetes", <i>Expert Opinion on Therapeutic Patents</i> , 9(6), pp. 701-709 (1999)
SW	57	Madsen, P., et al., "Advances in Non-Peptide Glucagon Receptor Antagonists", <i>Current Pharmaceutical Design</i> , 5, pp. 683-691 (1999)

Examiner Signature	<i>S. Wang</i>	Date Considered	5/18/07
--------------------	----------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003